MDAT

MDAT
Clinical data

Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name 5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxol-6-amine
CAS Number	101625-35-8
PubChem CID	36483
ChemSpider	33531
Chemical and physical data
Formula	C₁₁H₁₃NO₂
Molar mass	191.223 g/mol
3D model (Jmol)	Interactive image
SMILES C3Cc1cc2OCOc2cc1CC3N

6,7-Methylenedioxy-2-aminotetralin (MDAT) is a drug developed in the 1990s by a team at Purdue University led by David E. Nichols. It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity. Hence, MDAT is considered likely to be a non-neurotoxic, putative entactogen in humans.